Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Valentine Karen
 2. Date of Event Requiring Statement (Month/Day/Year)
06/04/2008		 3. Issuer Name and Ticker or Trading Symbol
ANTIGENICS INC /DE/ [agen]
(Last)
(First)
(Middle)
C/O ANTIGENICS INC., 3 FORBES RD		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
VP and General Counsel
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

LEXINGTON, MA 02421		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 10,106
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option, right to buy 03/22/2005(1) 03/22/2014 Common Stock 15,000 $ 10.17 D  
Stock Option, right to buy 03/07/2006(2) 03/07/2015 Common Stock 7,500 $ 6.3 D  
Stock Option, right to buy 01/01/2007(3) 01/01/2016 Common Stock 7,500 $ 4.76 D  
Stock Option, right to buy 03/22/2007(4) 03/22/2016 Common Stock 7,500 $ 5.13 D  
Stock Option, right to buy 09/15/2007(5) 09/15/2016 Common Stock 12,500 $ 1.63 D  
Stock Option, right to buy 12/04/2007(6) 12/04/2016 Common Stock 30,000 $ 2.03 D  
Restricted Stock 01/05/2009(7) 01/05/2017 Common Stock 5,209 $ 0 D  
Stock Option, right to buy 09/12/2008(8) 09/12/2017 Common Stock 48,900 $ 2.27 D  
Restricted Stock 07/10/2008(9) 01/10/2018 Common Stock 16,376 $ 0 D  
Restricted Stock 01/10/2009(10) 01/10/2018 Common Stock 16,375 $ 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Valentine Karen
C/O ANTIGENICS INC.
3 FORBES RD
LEXINGTON, MA 02421		       VP and General Counsel  

Signatures

Christine M. Klaskin, by Power of Attorney 06/09/2008
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Options vest in four equal annual installments beginning March 22, 2005.
(2) Options vest in four equal annual installments beginning March 7, 2006.
(3) Options vest in four equal annual installments beginning January 1, 2007.
(4) Options vest in three equal annual installments beginning March 22, 2007.
(5) Options vest 33% on September 15, 2007 and 67% on September 15, 2008.
(6) Options vest in four equal annual installments beginning December 4, 2007.
(7) Restricted Stock granted in accordance with the terms of the Antigenics Inc. 1999 Equity Incentive Plan, as amended, and vests on January 5, 2009.
(8) Options vest in four equal annual installments beginning September 12, 2008.
(9) Restricted Stock granted in accordance with the Antigenics Inc. 1999 Equity Incentive Plan, as amended and vests on July 10, 2008.
(10) Restricted Stock granted in accordance with the Antigenics Inc. 1999 Equity Incentive Plan, as amended, and vests on January 10, 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.